Back to Search
Start Over
Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma
Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma
- Source :
- Anticancer research. 41(9)
- Publication Year :
- 2021
-
Abstract
- Background/aim While there is increasing evidence supporting the role of several first- and second-line treatment regimens for advanced hepatocellular carcinomas (HCC), the clinical relevance of rechallenge treatment with previously administered drugs, however, remains to be explored. Patients and methods Five consecutive patients with advanced HCC who received lenvatinib rechallenge treatment after ramucirumab were assessed. Results All patients were clinically diagnosed with failure after ramucirumab treatment, and the frequencies of ramucirumab administration before lenvatinib re-administration ranged from 3 to 11. The alfa-fetoprotein level in four of five patients decreased 1 month after the lenvatinib rechallenge. Radiological findings via the modified Response Evaluation Criteria in Solid Tumors showed stable diseases in four patients and a partial response in one. Conclusion Rechallenge treatment with lenvatinib after ramucirumab can be effective, and may be a treatment option for HCC in cases wherein the disease progressed after an initial response to lenvatinib treatment.
- Subjects :
- Oncology
Male
Cancer Research
medicine.medical_specialty
Carcinoma, Hepatocellular
Antineoplastic Agents
Antibodies, Monoclonal, Humanized
Treatment failure
Ramucirumab
chemistry.chemical_compound
Internal medicine
medicine
Humans
Clinical significance
Treatment Failure
Aged
Retrospective Studies
Treatment regimen
business.industry
Phenylurea Compounds
Liver Neoplasms
Treatment options
General Medicine
Middle Aged
medicine.disease
digestive system diseases
Treatment Outcome
chemistry
Response Evaluation Criteria in Solid Tumors
Hepatocellular carcinoma
Quinolines
alpha-Fetoproteins
Lenvatinib
business
Subjects
Details
- ISSN :
- 17917530
- Volume :
- 41
- Issue :
- 9
- Database :
- OpenAIRE
- Journal :
- Anticancer research
- Accession number :
- edsair.doi.dedup.....0ca4e0b7670c1d1eee2c688f61d36054